Tag: New

Why This New Dementia Study Is a Huge Hit

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares rose sharply early Monday after the firm announced that its late-stage dementia study met its primary endpoint. Specifically, the results come from Acadia’s Phase 3 Harmony study evaluating pimavanserin for the treatment of dementia-related psychosis. The study met its primary endpoint, demonstrating a highly